Ono Pharmaceutical Co., Ltd. (Osaka, Japan), led by President and CEO Gyo Sagara, has announced a significant milestone today. The company has formalized an option and collaboration agreement with Numab…
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a pioneer in precision genetic medicine for rare diseases, has announced today that the U.S. Food and Drug Administration (FDA) has accepted and filed the…
In the AdFirst trial, Biotest’s fibrinogen concentrate (FC), BT524, successfully met the primary endpoint, demonstrating its efficacy in treating acquired fibrinogen deficiency (AFD) on par with standard care, while maintaining…
Today, GSK has announced the successful completion of its acquisition of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with respiratory and…
Today marks the completion of GSK’s acquisition of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical company dedicated to addressing the unmet medical needs of patients with respiratory and inflammatory conditions. As…
ResearchAndMarkets.com is pleased to announce the addition of “FDA Inspection” training to its offerings. This two-day seminar is meticulously crafted to equip professionals in the pharmaceutical, biopharmaceutical, biologics, and medical…
Zoetis, a global leader in animal health, has announced its financial results for the fourth quarter and full year 2023, along with full-year guidance for 2024. In the fourth quarter…
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has announced that the European Commission has granted conditional marketing authorization to CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy. CASGEVY is now approved for…
Bristol Myers Squibb has disclosed that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Augtyro™ (repotrectinib) to treat adult and pediatric patients…
Today marks the completion of AbbVie’s acquisition of ImmunoGen (NASDAQ: IMGN), solidifying ImmunoGen’s integration into AbbVie’s portfolio. Robert A. Michael, AbbVie’s president and chief operating officer, expressed enthusiasm about the…
Lupin Limited, a prominent global pharmaceutical company, has unveiled the launch of Bromfenac Ophthalmic Solution, 0.075%, following its approval by the United States Food and Drug Administration (U.S. FDA). This…
The significance of maintaining health and well-being cannot be overstated, especially for individuals living with epilepsy, where the impacts of poor physical health, mental well-being, and overall quality of life…